Companies › Humacyte
1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Acellular Tissue Engineered Vessel (ATEV) Tissue-engineered vascular graft for hemodialysis access | – | Phase 3 | End Stage Renal Disease (ESRD) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05908084 | Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | Genitourinary | Jun 2027 |
Cash of $80m on 2026-06-30; operating cash outflow about $96m a year; runway about 10 months at that burn, to Apr 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Genexine Innovacell TolerogenixX Vera Therapeutics Hansa Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.